Eli Lilly announced a $3.5 billion manufacturing campus in Lehigh Valley, Pennsylvania to produce retatrutide and future obesity injectables. The facility will house drug and device assembly for next‑generation weight‑loss therapies as Lilly ramps global supply ahead of anticipated demand. Company statements frame the plant as strategic capacity expansion to support multiple obesity franchises and improve vertical control of device‑drug integration. The investment underscores pharma’s move to secure manufacturing for high‑volume, chronic injectable therapies.